New Daily Pill Doubles Survival Time for Advanced Pancreatic Cancer Patients
Photo: Towfiqu barbhuiya / Unsplash
A groundbreaking medication called daraxonrasib has shown remarkable promise in a major clinical trial, doubling average survival time for advanced pancreatic cancer patients to 13.2 months compared to 6.6 months with standard chemotherapy. The encouraging results, presented at the American Society of Clinical Oncology's annual meeting, offer new hope for patients facing one of cancer's most challenging diagnoses.
A groundbreaking medication called daraxonrasib has shown remarkable promise in a major clinical trial, doubling average survival time for advanced pancreatic cancer patients to 13.2 months compared to 6.6 months with standard chemotherapy. The encouraging results, presented at the American Society of Clinical Oncology’s annual meeting, offer new hope for patients facing one of cancer’s most challenging diagnoses.